{"id":"meningococcal-acwy-conjugate-vaccine-menacwy","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site pain"},{"rate":"10-15","effect":"Injection site erythema"},{"rate":"10-15","effect":"Injection site swelling"},{"rate":"20-30","effect":"Myalgia"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-10","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains purified polysaccharide capsules from Neisseria meningitidis serogroups A, C, W, and Y conjugated to a diphtheria toxoid protein carrier. This conjugation enhances immunogenicity by promoting T-cell dependent B-cell responses, leading to robust production of bactericidal antibodies that protect against invasive meningococcal disease caused by these serogroups.","oneSentence":"MenACWY is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by linking polysaccharide capsules to a protein carrier.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:43.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y"}]},"trialDetails":[{"nctId":"NCT04502693","phase":"PHASE3","title":"Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-14","conditions":"Infections, Meningococcal","enrollment":3657},{"nctId":"NCT03135834","phase":"PHASE3","title":"A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-04-24","conditions":"Meningococcal Vaccine","enrollment":1610},{"nctId":"NCT01725217","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2012-11","conditions":"Meningococcal Disease","enrollment":198},{"nctId":"NCT04440163","phase":"PHASE3","title":"MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-17","conditions":"Meningococcal Vaccine","enrollment":2431},{"nctId":"NCT04239430","phase":"","title":"Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2020-11-26","conditions":"HIV/AIDS, Meningococcal Disease","enrollment":55},{"nctId":"NCT03433482","phase":"PHASE2","title":"A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-08-30","conditions":"Meningitis, Meningococcal","enrollment":1707},{"nctId":"NCT03652610","phase":"PHASE2","title":"A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-09-07","conditions":"Infections, Meningococcal","enrollment":996},{"nctId":"NCT03189745","phase":"PHASE3","title":"A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-08-01","conditions":"Meningococcal ACWY Disease","enrollment":229},{"nctId":"NCT01192997","phase":"PHASE2, PHASE3","title":"Comparison of Two Meningococcal ACWY Conjugate Vaccines","status":"COMPLETED","sponsor":"Public Health England","startDate":"2012-06","conditions":"Meningococcal Meningitis","enrollment":91},{"nctId":"NCT02986854","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-12-08","conditions":"Infections, Meningococcal","enrollment":704},{"nctId":"NCT02287688","phase":"","title":"Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-12-01","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":144},{"nctId":"NCT01934140","phase":"PHASE3","title":"Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-04","conditions":"Infections, Meningococcal","enrollment":311},{"nctId":"NCT01900899","phase":"PHASE3","title":"Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-07","conditions":"Infections, Meningococcal","enrollment":184},{"nctId":"NCT01682876","phase":"PHASE3","title":"Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-07","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":715},{"nctId":"NCT01962207","phase":"PHASE3","title":"The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10","conditions":"Infections, Meningococcal","enrollment":243},{"nctId":"NCT00329849","phase":"PHASE3","title":"Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-05","conditions":"Meningococcal Disease","enrollment":1500},{"nctId":"NCT00310856","phase":"PHASE2","title":"Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-06","conditions":"Meningococcal Meningitis","enrollment":175},{"nctId":"NCT01547715","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India","status":"COMPLETED","sponsor":"Novartis","startDate":"2012-03","conditions":"Bacterial Meningitis","enrollment":180},{"nctId":"NCT01214837","phase":"PHASE3","title":"Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-10","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":751},{"nctId":"NCT01766206","phase":"PHASE4","title":"Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-15","conditions":"Meningococcal Disease","enrollment":3948},{"nctId":"NCT00127855","phase":"PHASE2","title":"Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":409},{"nctId":"NCT02106390","phase":"PHASE3","title":"Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-06-05","conditions":"Infections, Meningococcal","enrollment":750},{"nctId":"NCT00356369","phase":"PHASE2","title":"Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-12-23","conditions":"Infections, Meningococcal","enrollment":500},{"nctId":"NCT00262041","phase":"PHASE2","title":"Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2004-10","conditions":"Prevention of Meningococcal Disease","enrollment":524},{"nctId":"NCT01345721","phase":"PHASE3","title":"Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-05","conditions":"Meningococcal Disease","enrollment":205},{"nctId":"NCT00196976","phase":"PHASE2","title":"Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-24","conditions":"Infections, Meningococcal","enrollment":461},{"nctId":"NCT01148017","phase":"PHASE3","title":"Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-07","conditions":"Meningococcal Meningitis","enrollment":433},{"nctId":"NCT00856297","phase":"PHASE3","title":"Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-02","conditions":"Meningococcal Meningitis","enrollment":389},{"nctId":"NCT01453348","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-10","conditions":"Meningococcal Disease, Meningococcal Meningitis, Hepatitis A","enrollment":252},{"nctId":"NCT01705379","phase":"","title":"Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older","status":"WITHDRAWN","sponsor":"Novartis Vaccines","startDate":"2013-03","conditions":"Meningococcal Disease","enrollment":""},{"nctId":"NCT01593514","phase":"PHASE4","title":"Understanding the Immune Response to Two Different Meningitis Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-12","conditions":"Meningitis, Meningococcal Disease, Septicaemia","enrollment":20},{"nctId":"NCT00126984","phase":"PHASE2","title":"Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-07","conditions":"Infections, Meningococcal","enrollment":508},{"nctId":"NCT00126945","phase":"PHASE2","title":"Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-08","conditions":"Infections, Meningococcal","enrollment":125},{"nctId":"NCT00196963","phase":"PHASE2","title":"Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03","conditions":"Infections, Meningococcal","enrollment":125},{"nctId":"NCT00196950","phase":"PHASE2","title":"Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-09","conditions":"Infections, Meningococcal","enrollment":50},{"nctId":"NCT00518180","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-07","conditions":"Meningococcal Meningitis, Human Papillomavirus Infection, Pertussis","enrollment":1620},{"nctId":"NCT01214850","phase":"PHASE3","title":"Novartis Vaccine and Diagnostics Carriage Trial","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-09","conditions":"N. Meningitidis Carriage","enrollment":2968},{"nctId":"NCT00560313","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-07","conditions":"Meningococcal Disease","enrollment":54},{"nctId":"NCT00616421","phase":"PHASE3","title":"Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-03","conditions":"Meningococcal Infections","enrollment":2907},{"nctId":"NCT00262028","phase":"PHASE2","title":"Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-04","conditions":"Prevention of Meningococcal Disease","enrollment":910},{"nctId":"NCT00310817","phase":"PHASE2","title":"Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-03","conditions":"Meningococcal Meningitis","enrollment":623},{"nctId":"NCT01994629","phase":"PHASE2","title":"Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-11","conditions":"Meningococcal Disease","enrollment":202},{"nctId":"NCT01973218","phase":"PHASE3","title":"Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-11","conditions":"Meningococcal Disease","enrollment":264},{"nctId":"NCT01452438","phase":"","title":"Safety Surveillance of MenACWY-CRM Vaccine in Children","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-09","conditions":"Meningococcal Disease","enrollment":393},{"nctId":"NCT01018732","phase":"PHASE2","title":"A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-01","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":155},{"nctId":"NCT00450437","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":"Meningococcal Infections, Meningococcal Meningitis","enrollment":3539},{"nctId":"NCT00901940","phase":"PHASE3","title":"Understanding the Immune Response to Meningitis Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2009-06","conditions":"Meningitis, Septicemia","enrollment":150},{"nctId":"NCT00601731","phase":"PHASE2","title":"Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-02","conditions":"Meningococcal Disease","enrollment":382},{"nctId":"NCT00488683","phase":"PHASE2","title":"B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-07","conditions":"Meningococcal Disease","enrollment":216},{"nctId":"NCT01410474","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-08","conditions":"Bacterial Meningitis","enrollment":341},{"nctId":"NCT00329901","phase":"PHASE3","title":"Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-04","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":1072},{"nctId":"NCT00262002","phase":"PHASE2","title":"Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2004-09","conditions":"Prevention of Meningococcal Disease","enrollment":601},{"nctId":"NCT00474487","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-05","conditions":"Meningococcal Meningitis, Meningococcal Infections","enrollment":2831},{"nctId":"NCT00474526","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":"Meningitis, Meningococcal","enrollment":4545},{"nctId":"NCT01466387","phase":"PHASE3","title":"A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-11","conditions":"Meningococcal Disease, Meningococcal Meningitis, Typhoid","enrollment":552},{"nctId":"NCT00667602","phase":"PHASE3","title":"Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-03","conditions":"Meningococcal Meningitis","enrollment":662},{"nctId":"NCT00626327","phase":"PHASE3","title":"Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-02","conditions":"Meningococcal Infections","enrollment":1630},{"nctId":"NCT01274897","phase":"PHASE3","title":"A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-12","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Menveo®"],"phase":"phase_3","status":"active","brandName":"Meningococcal ACWY Conjugate Vaccine, MenACWY","genericName":"Meningococcal ACWY Conjugate Vaccine, MenACWY","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"MenACWY is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by linking polysaccharide capsules to a protein carrier. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}